Journal of Cancer

Globally, esophageal cancer (EC) is one of the most common causes of cancer-related death [1, 2]. Collectively, the 5-year overall survival (OS) rate for all patients is 19% [2]. For non-operable, localized EC, definitive concurrent chemoradiotherapy (dCCRT) is usually the standard treatment approach. ................
................